8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Shareholder votes
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Investor Presentation
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Announces Establishment of New PDUFA Date for Deramiocel BLA
Announces Pricing of $150 Million Public Offering of Common Stock
Q1
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload